SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

XERAVA

INVA·Innoviva, Inc.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (FDA since 2018)
Time to market
Already on the market (approved in the US since 2018, in China since 2023).
Why 3/10
XERAVA is an approved, marketed drug with no pending regulatory decision, PDUFA date, or scheduled pivotal readout in the next ~12 months. It contributes a small fraction (about 3%) of Innoviva's total revenue, behind the company's larger GSK royalty stream and its other IST products GIAPREZA and XACDURO. Per the impact scoring rubric, an approved drug with no imminent binary catalyst defaults to 3-5, and the drug's modest revenue share places it at the lower end of that range.
Actionable Insight NEUTRAL

XERAVA has no scheduled binary catalyst to watch. The next relevant event for Innoviva overall is the Q3 2026 earnings call on November 11, 2026, which will report aggregate IST product sales. Investors interested in XERAVA-specific signals should track pediatric trial results (NCT06794541) and any updates to IDSA/SIS treatment guidelines, but neither provides a hard, dated binary for the stock.

Price Chart

Loading chart...

Executive Summary

XERAVA (eravacycline) is an FDA-approved intravenous antibiotic for complicated intra-abdominal infections (cIAI), originally developed by Tetraphase Pharmaceuticals and now marketed in the US by Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA). Despite its clinical utility against multi-drug resistant pathogens, XERAVA is a niche product with modest sales ($3.4M in Q3 2026 U.S. net product sales) and faces heavy competition from generic carbapenems and other branded antibiotics. For Innoviva, XERAVA is the smallest of three commercial products behind GIAPREZA and XACDURO, and the company's primary value driver remains its GSK royalty portfolio. No upcoming regulatory catalysts are expected for this drug.

How It Works

XERAVA is a synthetic fluorocycline antibiotic (part of the tetracycline family) given intravenously in hospitals. It kills bacteria by blocking their ability to produce the proteins they need to survive. Its chemical structure is modified to evade many common antibiotic-resistance mechanisms that have rendered older tetracyclines less effective.

Trial Status

XERAVA was approved by the FDA in August 2018 based on two Phase 3 trials (IGNITE 1 and IGNITE 4) that showed it was as effective as carbapenem antibiotics for complicated intra-abdominal infections (cIAI). A Phase 2 pediatric trial in patients aged 8-17 is ongoing (NCT06794541). An oral formulation was discontinued after a Phase 3 trial in urinary tract infections failed to meet its goals. Real-world evidence continues to be published, including subpopulation analyses and studies in carbapenem-resistant infections.

The Two-Sided Case

▲ Bull Case1
XERAVA addresses a clear unmet need: multi-drug resistant Gram-negative infections in hospitalized patients, a growing public health threat. It was named in the 2024 Surgical Infection Society guidelines as a recommended agent for empiric therapy in cIAI, which should support adoption. The drug benefits from QIDP (Qualified Infectious Disease Product) exclusivity extending to August 2028 under the GAIN Act, providing some regulatory protection. Innoviva's IST commercial platform continues to grow overall product sales 45% year-over-year in Q3 2026, suggesting improving commercial execution.
▼ Bear Case1
XERAVA is a very small contributor to Innoviva's business: only $3.4 million in Q3 2026 U.S. net product sales, or about 3.2% of the company's total quarterly revenue of $106.1 million. It competes against many well-established, cheaper generic antibiotics (meropenem, imipenem, piperacillin-tazobactam) and newer branded products like AbbVie's AVYCAZ. Hospital antibiotic markets are notoriously difficult to grow given pressure to use lowest-cost alternatives. Oral formulation was discontinued, limiting the drug to IV-only hospital use. The NCE (New Chemical Entity) exclusivity expired in August 2023, and the remaining patent/regulatory protection is finite.

Upcoming Catalysts

  • No hard, dated regulatory binary catalyst (PDUFA, AdComm, or pivotal readout) is scheduled for XERAVA in the next ~12 months. A Phase 2 pediatric safety trial is ongoing but has not disclosed a topline readout date. Innoviva presents IDWeek data in late 2026, but these are scientific presentations, not registration catalysts.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Innoviva, Inc. 8-K INVA ·Originating report

Sources · 11

Hover a chip for the title
1 accessdata.fda.gov2 drugs.com3 innovivaspecialtytherapeutics.com4 fiercepharma.com5 biospace.com6 companiesmarketcap.com7 pharsight.greyb.com8 cliffbio.com9 clinicaltrials.gov10 investor.inva.com11 innovivaspecialtytherapeutics.com